Synthego Says It Doesn’t Infringe Agilent CRISPR Patents

Time Stamp: October 6, 2021 2:59 PM
Source Node: 1120564
By Adam Lidgett (October 6, 2021, 6:59 PM EDT) — Genome engineering company Synthego Corp. wants a California federal court to find that its products relating to the breakthrough gene-editing technology CRISPR don’t infringe a pair of Agilent Technologies Inc. patents.

Synthego launched a declaratory judgment lawsuit Tuesday asking the court to find that it does not infringe U.S. Patent Nos. 10,337,001 and 10,900,034.

The suit said in June, Agilent asked Synthego if it wanted to license certain patents — including the two patents at issue in the lawsuit — related to guide RNAs.

Agilent said in a letter Synthego could benefit from Agilent patents, but gave Synthego a tight deadline…

Source: https://www.law360.com/ip/articles/1428820?utm_source=rss&utm_medium=rss&utm_campaign=section

Time Stamp:

More from Law360: Intellectual Property